Buprenorphine and naloxone combinations: The effects of three dose ratios in morphine-stabilized, opiate-dependent volunteers

Psychopharmacology

Volumn 141, Issue 1, 1999, Pages 37-46

  Mendelson, John ^a   Jones, Reese T ^a   Welm, Susette ^a   Baggott, Matthew ^a   Fernandez, Isabella ^a   Melby, Ann K ^a   Nath, Rajneesh P ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Buprenorphine; Dose ratio; Human; Naloxone; Opiate dependence

Indexed keywords

BUPRENORPHINE; NALOXONE; OPIATE;

ADULT; ARTICLE; CLINICAL ARTICLE; DOSE RESPONSE; DRUG EFFICACY; DRUG FORMULATION; DRUG POTENTIATION; DRUG WITHDRAWAL; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; OPIATE ADDICTION; PRIORITY JOURNAL; SUBLINGUAL DRUG ADMINISTRATION; WITHDRAWAL SYNDROME;

ADULT; AFFECT; BUPRENORPHINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; MORPHINE; NALOXONE; NARCOTIC ANTAGONISTS; NARCOTICS; OPIOID-RELATED DISORDERS; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 0032931922     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002130050804     Document Type: Article

References (46)

1. Amass L, Bickel WK, Crean JP, Higgins ST, Badger GJ (1996) Preferences for clinic privileges, retail items and social activities in an outpatient buprenorphine treatment. J Subst Abuse Treat 13:43-49
2. Bickel WK, Stitzer ML, Bigelow GE, Liebson IA, Jasinski DR, Johnson RE (1988) A clinical trial of buprenorphine: comparison with methadone in the detoxification of heroin addicts. Clin Pharmacol Ther 43:72-78
3. Eissenberg T, Greenwald MK, Johnson RE, Liebson IA, Bigelow GE, Stitzer ML (1996) Buprenorphine's physical dependence potential: antagonist-precipitated withdrawal in humans. J Pharmacol Exp Ther 276:449-459
4. Fraser HF, Isbell H (1960) Human pharmacology and addiction liabilities of phenazocine and levophenacylmorphan. Bull Narcot 12:15-23
5. Fudala PJ, Yu E, Macfadden W, Kampman K, Cornish J (1996) Evaluation of the effects of naloxone and buprenorphine in morphine-stabilized opiate addicts (Abstract). 97th Annual Meeting American Society for Clinical Pharmacology and Therapeutics, Lake Buena Vista, Fla. Clin Pharmacol Ther 59:210
6. Ghodse AH (1987) Analysis of epidemiological data on agonist-antagonist analgesics. Drug Alcohol Depend 20:375-383
7. Gilman AG, Rall TW, Nies AS, Taylor P (1990) Goodman and Gilman's the pharmacological basis of therapeutics, 8th edn. Pergamon Press, New York
8. Jasinski DR (1977) Assessment of the abuse potentiality of morphine-like drugs (methods used in man). In: Martin WR (ed) Drug addiction I. Springer, Berlin
9. Jasinski DR, Pevnick JS, Griffith JD (1978) Human pharmacology and abuse potential of the analgesic buprenorphine. Arch Gen Psychiatry 35:501-516
10. Jasinski DR, Fudala PJ, Johnson RE (1989) Sublingual versus subcutaneous buprenorphine in opiate abusers. Clin Pharmacol Ther 45:513-519
11. Johnson RE, Jaffe JH, Fudala PJ (1992) A controlled trial of buprenorphine treatment for opioid addiction. JAMA 267: 2750-2755
12. Kanof PD, Aronson MJ, Ness R, Cochrane KJ, Horvath TB, Handelsman L (1991) Levels of opioid physical dependence in heroin addicts. Drug Alcohol Depend 27:253-262
13. Kosten TR, Krystal JH, Charney DS, Price LH, Morgan CH, Kleber HD (1990) Opioid antagonist challenges in buprenorphine maintained patients. Drug Alcohol Depend 25:73-78
14. Kosten TR, Morgan C, Kleber HD (1991) Treatment of heroin addicts using buprenorphine. Am J Drug Alcohol Abuse 17: 119-128
15. Lavelle TL, Hammersley R, Forsyth A (1991) The use of buprenorphine and temazepam by drug injectors. J Addic Dis 10:5-14
16. Lewis JW (1985) Buprenorphine. Drug Alcohol Depend 14: 363-372
17. Ling W, Rawson RA, Compton MA (1994) Substitution pharmacotherapies for opioid addiction: from methadone to LAAM and buprenorphine. J Psychoact Drugs 26: 119-128
18. Ling W, Wesson DR, Charuvastra C, Klett CJ (1996) A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence. Arch Gen Psychiatry 53:401-407
19. Loimer N, Presslich O, Grunberger J, Linzmayer L (1991) Combined naloxone/methadone preparations for opiate substitution therapy. J Subst Abuse Treat 8:157-160
20. Martin WR, Eades CG, Thompson JA, Huppler RE, Gilbert PE (1976) The effects of morphine and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog. J Pharmacol Exp Ther 197:517-532
21. McNair DM, Lorr M, Doppleman LF (1971) Profile of Mood States. Educational and Industrial Testing Service, San Diego
22. Mello NK, Mendelson JH (1980) Buprenorphine suppresses heroin use by heroin addicts. Science 207:657-659
23. Mendelson J, Jones RT, Fernandez I, Welm S, Melby AK, Baggott MJ (1996) Buprenorphine and naloxone interactions in opiate-dependent volunteers. Clin Pharmacol Ther 60:105-114
24. Mendelson J, Jones RT, Welm S, Brown J, Batki SL (1997a) Buprenorphine and naloxone interactions in methadone maintenance patients. Biol Psychiatry 41:1095-1101
25. Mendelson J, Upton R, Lin E, Welm S, Jones RT (1997b) Sublingual buprenorphine and naloxone interactions in opiate-dependent patients stabilized on buprenorphine (Abstract). 98th Annual Meeting American Society for Clinical Pharmacology and Therapeutics, San Diego, Calif. Clin Pharmacol Ther 61:191
26. Mendelson J, Upton RA, Everhart ET, Jacob P, III, Jones RT (1997c) Bioavailability of sublingual buprenorphine. J Clin Pharmacol 37:31-37
27. Mendelson JH, Mello NK, Teoh SK, Lloyd-Jones JG, Clifford JM (1989) Naloxone suppresses buprenorphine stimulation of plasma prolactin. J Clin Psychopharmacol 9:105-109
28. Nigam AK, Srivastava RP, Saxena S, Chavan BS, Sundaram KR (1994) Naloxone-induced withdrawal in patients with buprenorphine dependence. Addiction 89:317-320
29. Nutt JG, Jasinski DR (1974) Methadone-naloxone mixtures for use in methadone maintenance programs. Clin Pharmacol Ther 15: 156-166
30. O'Brien CP, Greenstein R, Ternes J, Woody GE (1978) Clinical pharmacology of narcotic antagonists. Ann NY Acad Sci 311: 232-239
31. O'Connor JJ, Moloney E, Travers R, Campbell A (1988) Buprenorphine abuse among opiate addicts. Br J Addict 83: 1085-1087
32. Olley JE, Tiong GK (1988) Plasma levels of opioid material in man following sublingual and intravenous administration of buprenorphine: exogenous/endogenous opioid interaction? [letter]. J Pharm Pharmacol 40:666-667
33. Peachey JE, Lei H (1988) Assessment of opioid dependence with naloxone. Br J Addict 83:193-201
34. Preston KL, Bigelow GE, Liebson IA (1988) Buprenorphine and naloxone alone and in combination in opioid-dependent humans. Psychopharmacology 94:484-490
35. Preston KL, Bigelow GE, Liebson IA (1990) Effects of sublingually given naloxone in opioid-dependent human volunteers. Drug Alcohol Depend 25:27-34
36. Robinson GM, Dukes PD, Robinson BJ, Cooke RR, Mahoney GN (1993) The misuse of buprenorphine and a buprenorphine-naloxone combination in Wellington, New Zealand. Drug Alcohol Depend 33:81-86
37. Rolly G, Poelaert J, Mungroop H, Paelinck H (1986) A combination of buprenorphine and naloxone compared with buprenorphine administered intramuscularly in postoperative patients. J Int Med Res 14:148-152
38. Schuh KJ, Walsh SL, Bigelow GE, Preston KL, Stitzer ML (1996) Buprenorphine, morphine and naloxone effects during ascending morphine maintenance in humans. J Pharmacol Exp Ther 278:836-846
39. Strain EC, Preston KL, Liebson IA, Bigelow GE (1992) Acute effects of buprenorphine, hydromorphone and naloxone in methadone-maintained volunteers. J Pharmacol Exp Ther 261: 985-993
40. Strain EC, Stitzer ML, Liebson IA, Bigelow GE (1994) Buprenorphine versus methadone in the treatment of opioid-dependent cocaine users. Psychopharmacology 116:401-406
41. Strain EC, Preston KL, Liebson IA, Bigelow GE (1995) Buprenorphine effects in methadone-maintained volunteers: effects at two hours after methadone. J Pharmacol Exp Ther 272:628-638
42. Vanacker B, Vandermeersch E, Tomassen J (1986) Comparison of intramuscular buprenorphine and a buprenorphine/naloxone combination in the treatment of post-operative pain. Curr Med Res Opin 10:139-144
43. Walsh SL, Preston KL, Stitzer ML, Cone EJ, Bigelow GE (1994) Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther 55:569-580
44. Walsh SL, June HL, Schuh KJ, Preston KL, Bigelow GE, Stitzer ML (1995) Effects of buprenorphine and methadone in methadone-maintained subjects. Psychopharmacology 119: 268-276
45. Weinberg DS, Inturrisi CE, Reidenberg B, Moulin DE, Nip TJ, Wallenstein S, Houde RW, Foley KM (1988) Sublingual absorption of selected opioid analgesics. Clin Pharmacol Ther 44:335-342
46. Weinhold LL, Preston KL, Farre M, Liebson IA, Bigelow GE (1992) Buprenorphine alone and in combination with naloxone in nondependent humans. Drug Alcohol Depend 30:263-274